Baudax Bio Inc. (NASDAQ:BXRX) went up by 5.66% from its latest closing price compared to the recent 1-year high of $2.85. The company’s stock price has collected 9.71% of gains in the last five trading sessions. Press Release reported on 10/05/21 that Baudax Bio to Present at the NobleCon Pain Management Investor Forum
Is It Worth Investing in Baudax Bio Inc. (NASDAQ :BXRX) Right Now?
Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Baudax Bio Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $2.00. BXRX currently public float of 69.61M and currently shorts hold a 3.55% ratio of that float. Today, the average trading volume of BXRX was 3.06M shares.
BXRX’s Market Performance
BXRX stocks went up by 9.71% for the week, with a monthly drop of -5.76% and a quarterly performance of -6.44%, while its annual performance rate touched -79.07%. The volatility ratio for the week stands at 5.29% while the volatility levels for the past 30 days are set at 5.19% for Baudax Bio Inc.. The simple moving average for the period of the last 20 days is 2.06% for BXRX stocks with a simple moving average of -39.92% for the last 200 days.
Analysts’ Opinion of BXRX
Many brokerage firms have already submitted their reports for BXRX stocks, with JMP Securities repeating the rating for BXRX by listing it as a “Mkt Outperform.” The predicted price for BXRX in the upcoming period, according to JMP Securities is $13 based on the research report published on May 15th of the previous year 2020.
BXRX Trading at -1.96% from the 50-Day Moving Average
After a stumble in the market that brought BXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.51% of loss for the given period.
Volatility was left at 5.19%, however, over the last 30 days, the volatility rate increased by 5.29%, as shares sank -5.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.56% lower at present.
During the last 5 trading sessions, BXRX rose by +9.71%, which changed the moving average for the period of 200-days by -43.30% in comparison to the 20-day moving average, which settled at $0.5707. In addition, Baudax Bio Inc. saw -42.18% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BXRX starting from HENWOOD GERALDINE, who purchase 8,200 shares at the price of $0.59 back on Sep 22. After this action, HENWOOD GERALDINE now owns 364,507 shares of Baudax Bio Inc., valued at $4,798 using the latest closing price.
CHURCHILL WINSTON J, the Director of Baudax Bio Inc., purchase 100,000 shares at $0.63 during a trade that took place back on Aug 31, which means that CHURCHILL WINSTON J is holding 257,185 shares at $62,930 based on the most recent closing price.
Stock Fundamentals for BXRX
Current profitability levels for the company are sitting at:
- -11319.88 for the present operating margin
- -769.37 for the gross margin
The net margin for Baudax Bio Inc. stands at -15436.11. Equity return is now at value 229.30, with -53.90 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of -2.06, with the company’s debt to enterprise value settled at -9.64. The receivables turnover for the company is 19.33 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.03.